Please use this identifier to cite or link to this item:
https://hdl.handle.net/1/1414Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Verma, Abhishek K | - |
| dc.date.accessioned | 2019-05-27T02:06:35Z | en |
| dc.date.available | 2019-05-27T02:06:35Z | en |
| dc.date.issued | 2009-11 | - |
| dc.identifier.citation | Volume 79, Issue 11, pp. 773 - 774 | en |
| dc.identifier.uri | https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/1414 | en |
| dc.description.abstract | This article discusses two new agents, Dabigatran and Rivaroxaban and their use in orthopaedic thromboprophylaxis. Their safety, efficacy and cost effectiveness is also discussed. | en |
| dc.description.sponsorship | Haematology | en |
| dc.subject | Drug Therapy | en |
| dc.title | New agents for orthopaedic thromboprophylaxis: caution essential, but time will tell | en |
| dc.type | Journal Article | en |
| dc.identifier.doi | 10.1111/j.1445-2197.2009.05099.x | en |
| dc.description.pubmeduri | https://www.ncbi.nlm.nih.gov/pubmed/20078521 | en |
| dc.identifier.journaltitle | ANZ Journal of Surgery | en |
| dc.originaltype | Text | en |
| item.cerifentitytype | Publications | - |
| item.openairetype | Journal Article | - |
| item.grantfulltext | none | - |
| item.fulltext | No Fulltext | - |
| item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
| Appears in Collections: | Health Service Research | |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.